Tsvetelina Velikova

ORCID, self-asserted

ORCID 0000-0002-0593-1272

Publications

Citations

337

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

17 works in the graph, newest first.

Reduced Health‐Related Quality of Life in Patients With Systemic Sclerosis: A Cross‐Sectional Analysis of PROMIS Global Health Data From the International COVAD ‐2 e‐Survey
2025International Journal of Rheumatic DiseasesJournal0 citations10.1111/1756-185x.70101
Characteristics of emerging new autoimmune diseases after COVID ‐19 vaccination: A sub‐study by the COVAD group
2024International Journal of Rheumatic DiseasesJournalOpen access8 citations10.1111/1756-185x.15178
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
2024Lara D. VeekenJournalOpen access6 citations10.1093/rheumatology/keae520
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
2024Rheumatology Advances in PracticeJournalOpen access6 citations10.1093/rap/rkae028
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies
2024Rheumatology InternationalJournalOpen access4 citations10.1007/s00296-024-05562-z
Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
2024International Journal of Rheumatic DiseasesJournalOpen access3 citations10.1111/1756-185x.15161
Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis: results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
2024Rheumatology Advances in PracticeJournalOpen access1 citations10.1093/rap/rkae154
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
2024Lara D. VeekenJournalOpen access1 citations10.1093/rheumatology/keae128
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period—a cross-sequential study based on COVAD surveys
2023Lara D. VeekenJournalOpen access35 citations10.1093/rheumatology/kead144
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
2023Lara D. VeekenJournalOpen access18 citations10.1093/rheumatology/kead057
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
2023Lara D. VeekenJournalOpen access10 citations10.1093/rheumatology/kead180
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
2023Rheumatology InternationalJournalOpen access10 citations10.1007/s00296-023-05345-y
Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
2023Lara D. VeekenJournalOpen access8 citations10.1093/rheumatology/kead149
Flares of autoimmune rheumatic disease following COVID ‐19 infection: Observations from the COVAD study
2023International Journal of Rheumatic DiseasesJournalOpen access7 citations10.1111/1756-185x.14961
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
2023Lara D. VeekenJournalOpen access4 citations10.1093/rheumatology/kead382
POS0273 POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY
2023Annals of the Rheumatic DiseasesJournalOpen access1 citations10.1136/annrheumdis-2023-eular.4241
COVAD survey 2 long-term outcomes: unmet need and protocol
2022Rheumatology InternationalJournalOpen access44 citations10.1007/s00296-022-05157-6